All In MedTech

Device Trial Radar · NCT04870047

Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 171 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

171

Actual

Start

Sep 3, 2021

Primary completion

Dec 4, 2024

Study completion Dec 12, 2025

Sponsor

Lead sponsor
Phenox GmbHNot on our public-company list
Sponsor type
Industry
First posted
May 3, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess safety and efficacy of p64 MW HPC Flow Modulation Device under single antiplatelet therapy compared to p64 MW Flow Modulation Device under dual antiplatelet therapy.

Conditions

  • Intracranial Aneurysm

Interventions

  • Endovascular treatment of unruptured aneurysms with p64 MW HPC Flow Modulation DeviceDevice

    Patients suffering from a distal intracranial aneurysm will be treated endovascularly with the p64 MW HPC Flow Modulation Device.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of DWI lesionsTime frame: 48 hours (± 24 hours)

Locations

18 sites in 7 countries. Site status is shown where the registry gives one.

  • CHU Bordeaux

    Bordeaux, France

  • Hôpital Bicêtre

    Le Kremlin-Bicêtre, France

  • CHU de Lyon

    Lyon, France

15 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.